Is BCAB or ALZN more profitable?

BioAtla's return on equity of 0.00% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -289.67% Alzamend Neuro N/A -277.88% -184.20%

Is FBLG or BCAB more profitable?

BioAtla's return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -536.78% -225.12% BioAtla N/A N/A -289.67%

Do analysts prefer OSRH or BCAB?

BioAtla has a consensus price target of $200.00, suggesting a potential upside of 13,057.89%. Given BioAtla's stronger consensus rating and higher probable upside, analysts plainly believe BioAtla is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioAtla 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, OSRH or BCAB?

OSR has higher earnings, but lower revenue than BioAtla. OSR is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OSR $1.81M 5.05 -$27.06M -$0.37 N/A BioAtla $8.50M 0.30 -$59.61M -$25.45 N/A

Is OSRH or BCAB more profitable?

BioAtla has a net margin of 0.00% compared to OSR's net margin of -593.15%. BioAtla's return on equity of 0.00% beat OSR's return on equity. Company Net Margins Return on Equity Return on Assets OSR -593.15% -8.36% -6.24% BioAtla N/A N/A -289.67%

Is BCAB or MTVA more profitable?

BioAtla's return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -289.67% MetaVia N/A -209.67% -107.91%

BioAtla (BCAB) Competitors

$1.52 -0.07 (-4.40%)

As of 09/24/2026 01:05 PM Eastern

Compare

BCAB vs. ALZN, APRE, FBLG, OSRH, and MTVA

Should you buy BioAtla stock or one of its competitors? BioAtla's main competitors and comparable companies include Alzamend Neuro (ALZN), Aprea Therapeutics (APRE), FibroBiologics (FBLG), OSR (OSRH), and MetaVia (MTVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioAtla compare to Alzamend Neuro?

BioAtla (NASDAQ:BCAB) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, Alzamend Neuro had 1 more articles in the media than BioAtla. MarketBeat recorded 1 mentions for Alzamend Neuro and 0 mentions for BioAtla. Alzamend Neuro's average media sentiment score of 1.79 beat BioAtla's score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
BioAtla	Neutral
Alzamend Neuro	Very Positive

BioAtla presently has a consensus price target of $200.00, indicating a potential upside of 13,057.89%. Alzamend Neuro has a consensus price target of $28.00, indicating a potential upside of 1,438.46%. Given BioAtla's higher possible upside, research analysts plainly believe BioAtla is more favorable than Alzamend Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioAtla's return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-289.67%
Alzamend Neuro	N/A	-277.88%	-184.20%

BioAtla has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

Alzamend Neuro has lower revenue, but higher earnings than BioAtla. Alzamend Neuro is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.30	-$59.61M	-$25.45	N/A
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.30	N/A

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 9.3% of BioAtla shares are owned by company insiders. Comparatively, 1.4% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

BioAtla beats Alzamend Neuro on 7 of the 12 factors compared between the two stocks.

How does BioAtla compare to Aprea Therapeutics?

BioAtla (NASDAQ:BCAB) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

BioAtla has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. BioAtla's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-289.67%
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

Aprea Therapeutics has lower revenue, but higher earnings than BioAtla. Aprea Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.30	-$59.61M	-$25.45	N/A
Aprea Therapeutics	$290K	33.85	-$12.60M	-$1.08	N/A

BioAtla has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market.

In the previous week, Aprea Therapeutics had 4 more articles in the media than BioAtla. MarketBeat recorded 4 mentions for Aprea Therapeutics and 0 mentions for BioAtla. Aprea Therapeutics' average media sentiment score of 0.45 beat BioAtla's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
BioAtla	Neutral
Aprea Therapeutics	Neutral

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 9.3% of BioAtla shares are owned by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BioAtla presently has a consensus target price of $200.00, suggesting a potential upside of 13,057.89%. Aprea Therapeutics has a consensus target price of $3.07, suggesting a potential upside of 293.31%. Given BioAtla's higher possible upside, analysts plainly believe BioAtla is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Aprea Therapeutics beats BioAtla on 10 of the 16 factors compared between the two stocks.

How does BioAtla compare to FibroBiologics?

FibroBiologics (NASDAQ:FBLG) and BioAtla (NASDAQ:BCAB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

77.2% of BioAtla shares are held by institutional investors. 7.3% of FibroBiologics shares are held by insiders. Comparatively, 9.3% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

FibroBiologics currently has a consensus price target of $73.00, suggesting a potential upside of 5,267.65%. BioAtla has a consensus price target of $200.00, suggesting a potential upside of 13,057.89%. Given BioAtla's stronger consensus rating and higher probable upside, analysts plainly believe BioAtla is more favorable than FibroBiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioAtla's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-536.78%	-225.12%
BioAtla	N/A	N/A	-289.67%

FibroBiologics has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market.

In the previous week, FibroBiologics had 4 more articles in the media than BioAtla. MarketBeat recorded 4 mentions for FibroBiologics and 0 mentions for BioAtla. FibroBiologics' average media sentiment score of 0.50 beat BioAtla's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the media.

Company	Overall Sentiment
FibroBiologics	Neutral
BioAtla	Neutral

FibroBiologics has higher earnings, but lower revenue than BioAtla. FibroBiologics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A
BioAtla	$8.50M	0.30	-$59.61M	-$25.45	N/A

Summary

BioAtla beats FibroBiologics on 7 of the 13 factors compared between the two stocks.

How does BioAtla compare to OSR?

OSR (NASDAQ:OSRH) and BioAtla (NASDAQ:BCAB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

55.3% of OSR shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 36.9% of OSR shares are held by company insiders. Comparatively, 9.3% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BioAtla has a consensus price target of $200.00, suggesting a potential upside of 13,057.89%. Given BioAtla's stronger consensus rating and higher probable upside, analysts plainly believe BioAtla is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioAtla has a net margin of 0.00% compared to OSR's net margin of -593.15%. BioAtla's return on equity of 0.00% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
BioAtla	N/A	N/A	-289.67%

In the previous week, OSR's average media sentiment score of 0.00 equaled BioAtla'saverage media sentiment score.

Company	Overall Sentiment
OSR	Neutral
BioAtla	Neutral

OSR has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

OSR has higher earnings, but lower revenue than BioAtla. OSR is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$1.81M	5.05	-$27.06M	-$0.37	N/A
BioAtla	$8.50M	0.30	-$59.61M	-$25.45	N/A

Summary

BioAtla beats OSR on 9 of the 14 factors compared between the two stocks.

How does BioAtla compare to MetaVia?

BioAtla (NASDAQ:BCAB) and MetaVia (NASDAQ:MTVA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

BioAtla currently has a consensus target price of $200.00, suggesting a potential upside of 13,057.89%. MetaVia has a consensus target price of $20.00, suggesting a potential upside of 1,126.99%. Given BioAtla's higher probable upside, research analysts plainly believe BioAtla is more favorable than MetaVia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioAtla's return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-289.67%
MetaVia	N/A	-209.67%	-107.91%

In the previous week, MetaVia had 1 more articles in the media than BioAtla. MarketBeat recorded 1 mentions for MetaVia and 0 mentions for BioAtla. BioAtla's average media sentiment score of 0.00 equaled MetaVia'saverage media sentiment score.

Company	Overall Sentiment
BioAtla	Neutral
MetaVia	Neutral

MetaVia has lower revenue, but higher earnings than BioAtla. MetaVia is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.30	-$59.61M	-$25.45	N/A
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A

77.2% of BioAtla shares are held by institutional investors. Comparatively, 1.4% of MetaVia shares are held by institutional investors. 9.3% of BioAtla shares are held by company insiders. Comparatively, 0.6% of MetaVia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BioAtla has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Summary

BioAtla beats MetaVia on 6 of the 11 factors compared between the two stocks.

Get BioAtla News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAB vs. The Competition

Export

Metric	BioAtla	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.53M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.06	14.00	274.41	25.76
Price / Sales	0.30	1,342.42	688.46	106.29
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	-0.05	15.46	10.52	6.34
Net Income	-$59.61M	-$22.82M	$3.49B	$360.00M
7 Day Performance	-15.08%	-1.96%	-0.94%	-0.16%
1 Month Performance	-53.37%	-8.13%	-4.24%	-4.08%
1 Year Performance	-95.17%	32.15%	16.38%	5.97%

BioAtla Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAB BioAtla	1.4977 of 5 stars	$1.52 -4.4%	$200.00 +13,057.9%	-95.0%	$2.53M	$8.50M	N/A	60	Gap Down
ALZN Alzamend Neuro	3.4776 of 5 stars	$1.93 -0.5%	$28.00 +1,350.8%	-23.5%	$9.32M	N/A	N/A	6
APRE Aprea Therapeutics	2.7153 of 5 stars	$0.73 -0.9%	$3.07 +320.1%	-45.1%	$9.19M	$290K	N/A	8	Gap Up
FBLG FibroBiologics	2.1518 of 5 stars	$1.38 +1.1%	$73.00 +5,209.1%	-88.7%	$9.16M	N/A	N/A	15	Short Interest Increase
OSRH OSR	0.2087 of 5 stars	$0.25 +1.9%	N/A	-60.6%	$8.82M	$1.81M	N/A	N/A	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAB) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAtla (BCAB) Competitors

BCAB vs. ALZN, APRE, FBLG, OSRH, and MTVA

How does BioAtla compare to Alzamend Neuro?

Summary

How does BioAtla compare to Aprea Therapeutics?

Summary

How does BioAtla compare to FibroBiologics?

Summary

How does BioAtla compare to OSR?

Summary

How does BioAtla compare to MetaVia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAtla (BCAB) Competitors

BCAB vs. ALZN, APRE, FBLG, OSRH, and MTVA

How does BioAtla compare to Alzamend Neuro?

Does the media refer more to BCAB or ALZN?

Do analysts prefer BCAB or ALZN?

Is BCAB or ALZN more profitable?

Which has more risk and volatility, BCAB or ALZN?

Which has better valuation & earnings, BCAB or ALZN?

Do insiders & institutionals believe in BCAB or ALZN?

Summary

How does BioAtla compare to Aprea Therapeutics?

Is BCAB or APRE more profitable?

Which has better earnings & valuation, BCAB or APRE?

Which has more risk and volatility, BCAB or APRE?

Does the media prefer BCAB or APRE?

Do insiders and institutionals have more ownership in BCAB or APRE?

Do analysts rate BCAB or APRE?

Summary

How does BioAtla compare to FibroBiologics?

Do institutionals & insiders have more ownership in FBLG or BCAB?

Do analysts prefer FBLG or BCAB?

Is FBLG or BCAB more profitable?

Which has more volatility & risk, FBLG or BCAB?

Does the media favor FBLG or BCAB?

Which has preferable earnings & valuation, FBLG or BCAB?

Summary

How does BioAtla compare to OSR?

Do insiders & institutionals have more ownership in OSRH or BCAB?

Do analysts prefer OSRH or BCAB?

Is OSRH or BCAB more profitable?

Does the media favor OSRH or BCAB?

Which has more volatility and risk, OSRH or BCAB?

Which has better earnings & valuation, OSRH or BCAB?

Summary

How does BioAtla compare to MetaVia?

Do analysts recommend BCAB or MTVA?

Is BCAB or MTVA more profitable?

Does the media favor BCAB or MTVA?

Which has better earnings and valuation, BCAB or MTVA?

Do institutionals & insiders have more ownership in BCAB or MTVA?

Which has more volatility and risk, BCAB or MTVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools